KORU Medical Systems, Inc. KRMD has made a strategic move in its pursuit of expanding its footprint in the realm of large-volume subcutaneous infusion. The company announced a collaboration with a global pharmaceutical manufacturer, marking a significant step forward within this field.
Advancing Rare Disease Therapy
The collaboration aims to initiate a feasibility study utilizing KORU's Freedom Infusion System for an already commercialized rare diseasebiologic therapy. If successful, this study will pave the way for the development of a tailored Freedom System, facilitating the delivery of large-volume therapy through subcutaneous administration.
One key aspect of this collaboration is the exploration of new therapeutic settings, specifically the ambulatory infusion center and the ambulatory infusion suite in the United States, as well as the hospital setting in the European Union. This expansion beyond traditional home subcutaneous administration showcases the adaptability and versatility of KORU's technology.
Strategic Significance
The company, in this regard, highlighted the significance of venturing into new therapeutic territories and emphasized the potential life-changing impact of its Freedom Infusion System.
Looking ahead, KORU Medical aims to secure FDA clearance for the customized Freedom System within the next 12 months, on the heels of the success of the feasibility study. This regulatory milestone would further solidify the company's position as a prominent player in delivering innovative infusion solutions.
One Year Price Performance
Image Source: Zacks Investment Research
Market Prospects
Going by a Roots Analysis report, the global subcutaneous biologics market, valued at $113 billion in 2022, is projected to register a CAGR exceeding 40% during 2022-2035. This surge is fueled by the rapid expansion of biologics, one of the fastest-growing segments in the pharmaceutical industry. With more than 630 biologic products approved by the USFDA and thousands more in clinical evaluation, the market is witnessing a shift toward subcutaneous delivery. Advantages include improved patient adherence, cost savings, and innovative delivery technologies like prefilled syringes and wearable injectors.
Share Price Performance
Over the past year, shares of KORU Medical plunged 44.6% against the industry’s 16.5% growth.
Zacks Rank and Key Picks
KRMD currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Cardinal Health CAH, Stryker Corporation SYK and Cencora, Inc. COR.
Cardinal Health, carrying a Zacks Rank #1 (Strong Buy) at present, reported second-quarter fiscal 2024 adjusted earnings of $1.82 per share, which beat the Zacks Consensus Estimate by 16.7%. Revenues of $57.45 billion improved 11.6% on a year-over-year basis and also topped the Zacks Consensus Estimate by 1.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
CAH has a long-term estimated earnings growth rate of 15.3% compared with the industry’s 11.8% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.6%.
Stryker, carrying a Zacks Rank #2 (Buy) at present, reported a fourth-quarter 2023 adjusted EPS of $3.46, which beat the Zacks Consensus Estimate by 5.8%. Revenues of $5.8 billion outpaced the consensus estimate by 3.8%.
Stryker has an estimated earnings growth rate of 11.5% for 2025 compared with the S&P 500’s 9.9% increase. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.1%.
Cencora, carrying a Zacks Rank #2 at present, reported a first-quarter fiscal 2024 adjusted EPS of $3.28, which beat the Zacks Consensus Estimate by 14.7%. Revenues of $72.3 billion outpaced the Zacks Consensus Estimate by 5.1%.
COR has an earnings yield of 5.75% compared with the industry’s 1.85%. The company’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.7%.
Disclaimer: This article has been written with the assistance of Generative AI. However, the author has reviewed, revised, supplemented, and rewritten parts of this content to ensure its originality and the precision of the incorporated information.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows.
It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners UpStryker Corporation (SYK) : Free Stock Analysis Report
Cardinal Health, Inc. (CAH) : Free Stock Analysis Report
Cencora, Inc. (COR) : Free Stock Analysis Report
KORU Medical Systems Inc. (KRMD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
